市場調査レポート
商品コード
1173604
VT-1011新薬の考察と市場予測(2032年)VT-1011 Emerging Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
VT-1011新薬の考察と市場予測(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
当レポートでは、VT-1011新薬の主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)について調査分析し、作用機序、用法と用量、研究開発活動についての考察、市場予測などを提供しています。
"VT-1011 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VT-1011 for Presbyopia in the 7MM. A detailed picture of the VT-1011 for Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the VT-1011 for Presbyopia. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VT-1011 market forecast, analysis for Presbyopia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Presbyopia.
VT-1011 [Brimochol (carbachol + brimonidine tartrate)] is a lead investigational proprietary pupil-modulating eye drop for adults who suffer from presbyopia. The company is investigating the drug as a prescription to correct the loss of near vision.
Carbachol is a cholinergic agent that increases the depth of field, while brimonidine tartrate is an alpha-2 agonist that prevents iris dilation and inhibits ciliary body contraction. Together they produce a "pinhole effect," which reduces the size of the pupil so that only centrally focused light rays can enter the eye, thereby sharpening distant and near images while minimizing side effects. Brimonidine mitigates the side effects typically associated with cholinergic agents on the ciliary body, such as headache, brow ache, and myopic shift. Additionally, it also prolongs the pinhole effect of carbachol on the iris sphincter muscle by altering aqueous dynamics.
Brimochol, which is being developed by Visus Therapeutics, is the first presbyopia eye drop with the potential to last a minimum of 8 hours.
Currently the company has initiated a Phase III clinical trial for the safety and efficacy study of Brimochol in subjects with emmetropic phakic and pseudophakic presbyopia along with Phase III trials (BRIO-I and BRIO-II) for BRIMOCHOL PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of VT-1011 in Presbyopia in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of VT-1011 in Presbyopia covering trial interventions, trial conditions, trial status, start and completion dates.